201 related articles for article (PubMed ID: 27498862)
1. Integrated Patient-Derived Models Delineate Individualized Therapeutic Vulnerabilities of Pancreatic Cancer.
Witkiewicz AK; Balaji U; Eslinger C; McMillan E; Conway W; Posner B; Mills GB; O'Reilly EM; Knudsen ES
Cell Rep; 2016 Aug; 16(7):2017-31. PubMed ID: 27498862
[TBL] [Abstract][Full Text] [Related]
2. A pharmacogenomic analysis using L1000CDS
Choi EA; Choi YS; Lee EJ; Singh SR; Kim SC; Chang S
Cancer Lett; 2019 Nov; 465():82-93. PubMed ID: 31404615
[TBL] [Abstract][Full Text] [Related]
3. Trametinib and Hydroxychloroquine (HCQ) Combination Treatment in KRAS-Mutated Advanced Pancreatic Adenocarcinoma: Detailed Description of Two Cases.
Xavier CB; Marchetti KR; Castria TB; Jardim DLF; Fernandes GS
J Gastrointest Cancer; 2021 Mar; 52(1):374-380. PubMed ID: 33225411
[TBL] [Abstract][Full Text] [Related]
4. Pancreatic cancer cell lines as patient-derived avatars: genetic characterisation and functional utility.
Knudsen ES; Balaji U; Mannakee B; Vail P; Eslinger C; Moxom C; Mansour J; Witkiewicz AK
Gut; 2018 Mar; 67(3):508-520. PubMed ID: 28073890
[TBL] [Abstract][Full Text] [Related]
5. A tunable delivery platform to provide local chemotherapy for pancreatic ductal adenocarcinoma.
Indolfi L; Ligorio M; Ting DT; Xega K; Tzafriri AR; Bersani F; Aceto N; Thapar V; Fuchs BC; Deshpande V; Baker AB; Ferrone CR; Haber DA; Langer R; Clark JW; Edelman ER
Biomaterials; 2016 Jul; 93():71-82. PubMed ID: 27082874
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of Aurora Kinase A Induces Necroptosis in Pancreatic Carcinoma.
Xie Y; Zhu S; Zhong M; Yang M; Sun X; Liu J; Kroemer G; Lotze M; Zeh HJ; Kang R; Tang D
Gastroenterology; 2017 Nov; 153(5):1429-1443.e5. PubMed ID: 28764929
[TBL] [Abstract][Full Text] [Related]
7. Pancreas Cancer Precision Treatment Using Avatar Mice from a Bioinformatics Perspective.
Perales-Patón J; Piñeiro-Yañez E; Tejero H; López-Casas PP; Hidalgo M; Gómez-López G; Al-Shahrour F
Public Health Genomics; 2017; 20(2):81-91. PubMed ID: 28858862
[TBL] [Abstract][Full Text] [Related]
8. A MEK/PI3K/HDAC inhibitor combination therapy for KRAS mutant pancreatic cancer cells.
Ischenko I; Petrenko O; Hayman MJ
Oncotarget; 2015 Jun; 6(18):15814-27. PubMed ID: 26158412
[TBL] [Abstract][Full Text] [Related]
9. Generation and application of patient-derived xenograft models in pancreatic cancer research.
Wang CF; Shi XJ
Chin Med J (Engl); 2019 Nov; 132(22):2729-2736. PubMed ID: 31725451
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic potential of taxanes in the treatment of metastatic pancreatic cancer.
Lemstrova R; Melichar B; Mohelnikova-Duchonova B
Cancer Chemother Pharmacol; 2016 Dec; 78(6):1101-1111. PubMed ID: 27250969
[TBL] [Abstract][Full Text] [Related]
11. SOX2 functions as a molecular rheostat to control the growth, tumorigenicity and drug responses of pancreatic ductal adenocarcinoma cells.
Wuebben EL; Wilder PJ; Cox JL; Grunkemeyer JA; Caffrey T; Hollingsworth MA; Rizzino A
Oncotarget; 2016 Jun; 7(23):34890-906. PubMed ID: 27145457
[TBL] [Abstract][Full Text] [Related]
12. Speeding towards individualized treatment for pancreatic cancer by taking an alternative road.
Iovanna J; Dusetti N
Cancer Lett; 2017 Dec; 410():63-67. PubMed ID: 28947138
[TBL] [Abstract][Full Text] [Related]
13. Genomic characterization of patient-derived xenograft models established from fine needle aspirate biopsies of a primary pancreatic ductal adenocarcinoma and from patient-matched metastatic sites.
Allaway RJ; Fischer DA; de Abreu FB; Gardner TB; Gordon SR; Barth RJ; Colacchio TA; Wood M; Kacsoh BZ; Bouley SJ; Cui J; Hamilton J; Choi JA; Lange JT; Peterson JD; Padmanabhan V; Tomlinson CR; Tsongalis GJ; Suriawinata AA; Greene CS; Sanchez Y; Smith KD
Oncotarget; 2016 Mar; 7(13):17087-102. PubMed ID: 26934555
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic Landscape in Pancreatic Ductal Adenocarcinoma: On the Way to Overcoming Drug Resistance?
Ciernikova S; Earl J; García Bermejo ML; Stevurkova V; Carrato A; Smolkova B
Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32521716
[TBL] [Abstract][Full Text] [Related]
15. Mesothelin and TGF-α predict pancreatic cancer cell sensitivity to EGFR inhibitors and effective combination treatment with trametinib.
Poteet E; Liu D; Liang Z; Van Buren G; Chen C; Yao Q
PLoS One; 2019; 14(3):e0213294. PubMed ID: 30921351
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC).
Chandana S; Babiker HM; Mahadevan D
Expert Opin Investig Drugs; 2019 Feb; 28(2):161-177. PubMed ID: 30539678
[TBL] [Abstract][Full Text] [Related]
17. Profiling of conditionally reprogrammed cell lines for in vitro chemotherapy response prediction of pancreatic cancer.
Lee HS; Kim E; Lee J; Park SJ; Hwang HK; Park CH; Jo SY; Kang CM; Hong SM; Kang H; Jo JH; Cho IR; Chung MJ; Park JY; Park SW; Song SY; Han JM; Kim S; Bang S
EBioMedicine; 2021 Mar; 65():103218. PubMed ID: 33639403
[TBL] [Abstract][Full Text] [Related]
18.
Bush KT; Boichard A; Tsigelny IF
Anticancer Res; 2018 Apr; 38(4):1967-1977. PubMed ID: 29599312
[TBL] [Abstract][Full Text] [Related]
19. Everolimus for the treatment of advanced pancreatic ductal adenocarcinoma (PDAC).
Babiker HM; Karass M; Recio-Boiles A; Chandana SR; McBride A; Mahadevan D
Expert Opin Investig Drugs; 2019 Jul; 28(7):583-592. PubMed ID: 31215251
[No Abstract] [Full Text] [Related]
20. Targeted delivery of chemotherapy using HSP90 inhibitor drug conjugates is highly active against pancreatic cancer models.
Bobrov E; Skobeleva N; Restifo D; Beglyarova N; Cai KQ; Handorf E; Campbell K; Proia DA; Khazak V; Golemis EA; Astsaturov I
Oncotarget; 2017 Jan; 8(3):4399-4409. PubMed ID: 27779106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
